# Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs

> **NCT04943588** · — · RECRUITING · sponsor: **Queen Mary University of London** · enrollment: 25000 (estimated)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DIAGNOSTIC_TEST:** HCV RNA (PCR)
- **DIAGNOSTIC_TEST:** HCV Antibody test (Point of care)
- **DIAGNOSTIC_TEST:** AST/ALT and platelets measurement

## Key facts

- **NCT ID:** NCT04943588
- **Lead sponsor:** Queen Mary University of London
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2021-11-01
- **Primary completion:** 2026-01-30
- **Final completion:** 2026-01-30
- **Target enrollment:** 25000 (ESTIMATED)
- **Last updated:** 2025-03-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04943588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04943588, "Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04943588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*